Idarucizumab for Reversal of Dabigatran

LAUR Repository

Show simple item record

dc.contributor.author Sheikh‑Taha, Marwan
dc.date.accessioned 2019-10-16T07:13:33Z
dc.date.available 2019-10-16T07:13:33Z
dc.date.copyright 2019 en_US
dc.date.issued 2019-10-16
dc.identifier.issn 1175-3277 en_US
dc.identifier.uri http://hdl.handle.net/10725/11455
dc.description.abstract Background Idarucizumab is used to reverse the effects of dabigatran. Information on the use of idarucizumab in the clinical setting remains very limited. Objective The objective of this study was to describe clinical experience with idarucizumab in a large medical teaching center in the USA. Methods Patients who received idarucizumab to reverse the effects of dabigatran between 1 January 2016 and 30 June 2018 were studied. In patients with major bleeding, the efficacy of idarucizumab was assessed using criteria of the International Society of Thrombosis and Hemostasis Scientific and Standardization Subcommittee. The course of treatment and clinical outcomes in patients who received idarucizumab for emergency surgery or procedures are described. Results In total, 13 patients received idarucizumab for atrial fibrillation during the study period. Their mean age was 77.5 ± 7.1 years, and 12 (92.3%) were men. Idarucizumab was used in 11 patients for major bleeding events and in two patients for emergency surgery or procedures. Intracranial hemorrhage (n = 6) and gastrointestinal bleed (n = 2) were the most common types of bleeding. Clinical hemostasis was achieved in 8 of 11 (72.7%) patients with major bleeding. One patient with acute kidney injury needed two doses of the reversal agent to achieve hemostasis. One patient underwent open heart surgery and developed postoperative hemorrhage despite receiving idarucizumab. None of the patients experienced thrombotic complications or side effects that could be attributed to idarucizumab. Conclusion Real-world experience in a US hospital with the use of idarucizumab in emergency situations requiring the reversal of the effects of dabigatran is described. Idarucizumab represents an exciting new antidote for dabigatran, but clinical efficacy and cost-effectiveness data remain lacking. en_US
dc.language.iso en en_US
dc.title Idarucizumab for Reversal of Dabigatran en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle Single-Center Real-World Experience en_US
dc.author.school SOP en_US
dc.author.idnumber 199410150 en_US
dc.author.department Pharmacy Practice en_US
dc.description.embargo N/A en_US
dc.relation.journal American Journal of Cardiovascular Drugs en_US
dc.journal.volume 19 en_US
dc.journal.issue 1 en_US
dc.article.pages 59-64 en_US
dc.identifier.doi https://doi.org/10.1007/s40256-018-0300-5 en_US
dc.identifier.ctation Sheikh-Taha, M. (2019). Idarucizumab for reversal of dabigatran: single-center real-world experience. American Journal of Cardiovascular Drugs, 19(1), 59-64. en_US
dc.author.email marwan.taha@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://link.springer.com/article/10.1007/s40256-018-0300-5 en_US
dc.orcid.id https://orcid.org/0000-0002-8037-1201 en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account